Stocks

Merck Licenses SciBrunch's KRAS Inhibitor for Up to $2.13 Billion

Guavy AI Editorial Team Published September 28, 2026

Instruments

MRK

Merck has licensed an investigational KRAS G12D inhibitor from SciBrunch Therapeutics Co., Ltd. for $400 million upfront.

The agreement, announced in a press release statement, includes milestone payments related to development, commercialization, and other activities across multiple indications.

Under the deal, SciBrunch will receive up to $2.13 billion, including the upfront payment of $400 million, making it one of Merck's most significant partnerships to date.

SPR2015 is a molecular glue KRAS G12D inhibitor that has demonstrated nanomolar antiproliferative activities in various KRAS G12D-mutant cell lines, and has shown antitumor efficacy as a monotherapy across multiple in vivo cell-derived and patient-derived xenograft models.

George Addona, senior vice president of discovery, preclinical development and translational medicine at Merck Research Laboratories, said the agreement 'complements and diversifies our expanding pipeline of precision targeted candidates with SPR2015.'

Merck Licenses SciBrunch's KRAS Inhibitor for Up to $2.13 Billion

Thermal Interface Materials Market Sees Rapid Growth as Demand for Efficient Thermal Management Skyrockets

Honeywell Unveils P40 Upgrade for F-35 Fighter Jets with Enhanced Cooling Capacity

OT Cybersecurity Readiness Gap Exposed in Honeywell Report